Single-agent carboplatin AUC10 in metastatic seminoma: A multi-centre UK study of 216 patients.

Radiotherapy and cisplatin-based combination chemotherapy are accepted standard-of-care treatments for metastatic seminoma with excellent survival outcomes but with established short- and long-term morbidity. Carboplatin monotherapy may be a less toxic alternative; however early historic studies at AUC7 showed inferior outcomes. To evaluate multi-institutional data on and toxicity and longer-term survival for metastatic seminoma patients treated with the single-agent carboplatin AUC10. We undertook a multi-institutional analysis incorporating all men with the International Germ Cell Cancer Collaborative Group good-prognosis metastatic seminoma treated until 2018. Carboplatin AUC10 was given every 21 days. Toxicity, progression-free survival (PFS), disease-specific survival (DSS) and overall survival were noted. Variables predictive of progression were identified. 216 patients were treated. The three-year PFS rate was 96.5%, and five-year DSS was 98.3%. There were seven relapses, of which 5 were successfully salvaged with further chemotherapy ± surgery, and three non-seminoma-related deaths. There were no treatment-related deaths. Of 148/216 evaluable patients for toxicity, 37% and 27% suffered >/ = grade III neutropenia and thrombocytopenia, respectively. Twelve percent of patients needed a platelet or blood transfusion (or both). The incidence of febrile neutropenia was 5%. For metastatic seminoma, carboplatin AUC10 harbours a similar oncological efficacy to established therapies, with a low failure risk. The major acute toxicity was myelosuppression. Our study establishes carboplatin AUC10 as another standard-of-care treatment option for good-prognosis metastatic seminoma, with a potentially lower toxicity profile than other therapies. Copyright © 2020 Elsevier Ltd. All rights reserved.

Citation

Constantine Alifrangis, Anand Sharma, Shafi Chowdhury, Sarah Duncan, Marina Milic, Andrew Gogbashian, Samita Agarwal, Anju Sahdev, Peter Wilson, Stephen Harland, Sara Stoneham, Michelle Lockley, Gordon Rustin, Timothy Oliver, Daniel Berney, Jonathan Shamash. Single-agent carboplatin AUC10 in metastatic seminoma: A multi-centre UK study of 216 patients. European journal of cancer (Oxford, England : 1990). 2022 Mar;164:105-113

Mesh Tags

Substances

PMID: 33041185

search → result